Development of a very rapid diagnostic test for malaria, based on break-through detection technology and new biomarkers of infection.

Projektinformationen

MalaDiag

ID Finanzhilfevereinbarung: 663824

DOI 10.3030/663824

Abgeschlossenes Projekt

EK-Unterschriftsdatum 26 Februar 2015

Startdatum 1 Dezember 2014

Enddatum 31 Mai 2015

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

VAXIMAX
France

Ziel

The overall project objective is to develop and bring to market a very rapid diagnostic test (V-RDT) for malaria, based on break-through detection technology and particularly relevant biomarkers of infection.

Our ambition is for our diagnostic device to become the reference technology in all malaria endemic areas.

A key advantage of our approach lies in the combination of an innovative detection device with novel biomarkers that should significantly improve the quality of testing and the ability to implement mass testing campaigns.

Our device is expected to overcome most shortcomings identified in devices currently on the market. The expected added value of our proposed diagnostic device to users is multiple including:
• Rapidity: 1 minute vs. 15-20 minutes required for most current tests. This is a major competitive advantage for cross-sectional testing necessary for eradication efforts;
• High sensitivity including quantitative evaluations (picomolar detection);
• Several simultaneous measures to distinguish parasite species (P. falciparum / P. vivax);
• Infection parameters (parasite density and antibody response): the comprehensive nature of our diagnostic read-outs provide information on prognosis and/or therapeutic response in addition to simple yes/no diagnoses; and
• Functional and reliable in expected field conditions (tropical environments). .

Wissenschaftliches Gebiet

• medical and health sciences › health sciences › infectious diseases › malaria

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Thema/Themen

• PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2014-2015

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2014

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

VAXIMAX

• Netto-EU-Beitrag: € 50 000,00
• Adresse: 4 RUE PIERRE FONTAINE CAMPUS 3 ; 91058 Evry ; Frankreich
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Ile-de-France › Ile-de-France › Essonne
• Region: Ile-de-France › Ile-de-France › Essonne
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00

Beteiligte (1)

METEMIS DEVELOPMENT

Frankreich

• Netto-EU-Beitrag: € 0,00
• Adresse: 1 RUE PIERRE FONTAINE BAT 1 ; 91000 EVRY
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Ile-de-France › Ile-de-France › Essonne
• Region: Ile-de-France › Ile-de-France › Essonne
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: Keine Daten